Full-Time
Senior Clinical Research Nurse
Posted on 8/17/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$30.70 - $55.40/hr
North Chicago, IL, USA
In Person
Bachelor's, Associate's
 Medical, Clinical & Veterinary (1) |
|---|
 Biology & Biotech (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- Associate Degree in Nursing is required.
- Five or more years of nursing experience and/or more than four years of work experience in a clinical research environment is required.
- Knowledge of patient-care fundamentals, including aseptic principles and techniques, is required.
- Ability to provide direct patient care professionally and respectfully is required.
- Ability to read documents or instruments is required.
- Ability to exercise discretion and confidentiality while handling sensitive situations is required.
- Ability to perform multiple concurrent tasks with occasional interruptions is required.
- Function as a licensed registered nurse providing care and assessments for healthy volunteers and patients.
- Disseminate new documentation, performance-improvement, and PIMS-upgrade information to clinical research nurses on the unit.
- Provide study support within a defined scope to managers, clinical research nurse coordinators, investigators and sub-investigators, unit personnel, and ancillary staff.
- Facilitate and participate in the execution of Phase I clinical research study activities.
- Maintain the safety and confidentiality of study subjects throughout each study.
- Evaluate adverse events and manage safety-reporting activities in a timely manner.
- Review protocols and informed consent forms for scheduled studies.
- Identify and communicate potential issues to appropriate personnel.
- Conduct protocol-required nursing study activities in compliance with corporate, divisional, and departmental standard operating procedures and external Code of Federal Regulations, International Council for Harmonisation, and Good Clinical Practice guidelines.
- Coordinate study-specific nursing activities with the Principal Investigator, study physicians, Recruiting/Screening, Data Systems, and other personnel.
- Participate in quality and compliance improvement initiatives and provide feedback as a nursing subject-matter expert.
- Maintain accurate and complete source data in PIMS and other source documents, and facilitate resolution of discrepancies or issues.
- Assist with protocol-specific training for study personnel before study activities.
- Facilitate training of new nursing personnel and keep management informed of trainee progress.
- Implement changes to activity schedules based on the strategic plan.
- Assist with the informed-consent process for study subjects.
- Resolve study-related questions and mitigate issues with appropriate clinical research personnel.
- Maintain study forms and tools for accurate tracking and documentation of study information.
- Provide guidance or direction for protocol-related activities and escalate situations requiring further intervention.
- Train and participate in trial-related activities from initial entry through complete follow-up of patients enrolled in research protocols.
- Educate team members and provide training on revised or updated processes.
- Develop training documents and provide in-service education to nursing units and laboratory staff regarding upcoming and ongoing protocols.
- Report adverse drug reactions and submit appropriate documentation.
- Provide direct care to research patients, including drug administration, laboratory draws, appointment coordination, follow-up, and side-effect management.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $16.99 billion, up 10.2%, with EPS of $3.65.
- AbbVie raised 2026 guidance to $13.87-$14.07 after broad strength across immunology and neuroscience.
- Rinvoq and Skyrizi both grew above 23% operationally, showing durable post-Humira momentum.
What critics are saying
- Humira sales fell 36.1% in Q2 2026; biosimilars keep compressing cash flows.
- Imbruvica dropped 29.4% in Q2 2026, exposing oncology weakness and IRA pricing damage.
- Apogee dilutes adjusted EPS through 2027; if Skyrizi stalls, AbbVie loses its bridge.
What makes AbbVie unique
- Skyrizi and Rinvoq delivered $8.0 billion in Q2 2026, replacing Humira.
- AbbVie completed Apogee on September 3, 2026, adding long-acting immunology assets.
- Etentamig posted 74% response in Phase 3 multiple myeloma, broadening oncology optionality.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%AbbVie has dramatically shifted its focus away from Humira, its once-flagship drug now facing biosimilar competition. On the company's July 2026 earnings call, Humira received just one sentence, noting global sales of $706 million, down 36.1% operationally but in line with expectations. This marks a stark change from previous quarters when management detailed the reasons behind Humira's decline, including biosimilar competition and molecule compression in the US market. AbbVie now emphasises growth drivers instead. Skyrizi generated $5.5 billion in Q2 2026, whilst Rinvoq exceeded $2.5 billion, both growing above 20% operationally. The company also acquired Apogee Therapeutics in September 2026. Despite the reduced attention, Humira still contributes approximately 4% of AbbVie's quarterly revenue of nearly $17 billion, though management no longer publicly projects its ultimate decline trajectory.
Israel Englander's Millennium Management more than doubled its stakes in AbbVie and Costco during the second quarter. AbbVie's revenue grew 10.2% year-over-year to $17 billion in Q2, driven by immunology drugs Skyrizi and Rinvoq. The company recently acquired Apogee Therapeutics for $10.9 billion in cash and is developing ABBV-295, a monthly weight-loss treatment. AbbVie is a Dividend King with over 50 consecutive years of payout increases. Costco's Q3 fiscal 2026 revenue rose 11.6% to $70.5 billion, with comparable sales up 9.8%. The company has raised dividends for 22 consecutive years. However, Costco shares are down 4% over the past year whilst trading at 40.8 times forward earnings, above the consumer staples average of 21.6 times. Both companies maintain strong fundamentals despite different market challenges.
AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.
The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.
AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.